HOME >> MEDICINE >> NEWS
New radioimmunotherapy drug proves highly effective for killing off B cell non-Hodgkins lymphoma

ROCHESTER, MINN. -- A Mayo Clinic study indicates the first of a new class of drugs involving radioimmunotherapy benefited a significant number of patients with low-grade B cell non-Hodgkins lymphoma who have exhausted treatment options.

The study, published in the May 15, 2002, issue of Journal of Clinical Oncology, investigated the ability of the drug Zevalin to hone in on and kill off the non-Hodgkins lymphoma B cells. Zevalin is the first radioimmunotherapy drug developed specifically to fight this common but usually fatal cancer of the lymph glands that, for unknown reasons, is on the increase in the United States. About 56,000 people are diagnosed with this cancer annually.

The randomized study involved 143 patients with B cell non-Hodgkins lymphoma who had previously failed the standard chemotherapy treatments. The study found that 80 percent of patients who received Zevalin experienced a positive response in that their tumor shrunk. That compared to a 56 percent response rate in patients receiving only Rituxan, another drug used to treat the cancer.

Most noteworthy, 30 percent of the patients receiving Zevalin achieved complete remission with no evidence of the cancer present, compared to only 16 percent of patients taking Rituxan.

Radioimmunotherapy combines monoclonal antibodies, which are antibodies produced in a laboratory to react against a cancer cell, with the ability of radiation to kill off cancer cells. The mixture of radiation and antibodies is given intravenously and travels through the bloodstream to the cancer cells.

Unlike chemotherapy which goes through the whole body, Zevalin carries the radiation payload directly to the tumor, says Thomas Witzig, M.D., a Mayo Clinic hematologist. The drug radiates only about a five millimeter area around the tumor.

Along with its ability to hone in on cancer cells, the drug is easier on patients physically.

One treatment is required on an outpatient ba
'"/>

Contact: Mary Lawson
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
13-May-2002


Page: 1 2

Related medicine news :

1. New radioimmunotherapy cancer treatment
2. Hormonal treatment improves survival in high-risk prostate cancer patients
3. Growth hormone treatment improves symptoms of metabolic disorder in postmenopausal women
4. MRI proves useful in assessment of suspected breast cancer patients
5. New substance that improves the photodetection of bladder cancer gains market approval
6. Most advanced CT scanner improves imaging of heart, avoids need for surgical inspection
7. Columbia study finds hemophilia therapy dramatically improves outcomes for bleeding stroke
8. New test improves detection of bladder cancer
9. New mosquito control strategy proves successful against dengue fever
10. Study proves catheter ablation safe for patients
11. Adding radiation therapy to chemotherapy improves survival in patients with high-risk breast cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... Compliance and Safety for the President’s Malaria Initiative (PMI) Africa Indoor Residual ... Innovation to Action Award. , The Innovation to Action Award, a USAID ...
(Date:9/19/2017)... ... 2017 , ... MelaKids, a Laredo-based company, has introduced a new concept for ... Nature gives us a full supply of melanin – in the back of the ... glare-reducing pigment; however, around the age of thirty, we develop a yellow-brown pigment in ...
(Date:9/19/2017)... ... 19, 2017 , ... The Workgroup for Electronic Data Interchange (WEDI) , ... in healthcare information exchange and a trusted advisor to the U.S. Department of Health ... entitled Barriers to Adoption of the ERA and EFT Transactions . , ...
(Date:9/19/2017)... ... ... Public outrage over the toxins that exist in tap water and the ... industry itself to research, develop and ultimately supply consumers with healthy drinking water alternatives. ... natural alkaline water technologies, water filtration systems, and consumer education. ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... TX, announces the launch of its magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone ... the first in the U.S. to incorporate magnesium, a critical property for bone ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)...  Medical professionals are expected to continuously ... their patients. Medical simulations offer clinicians the ... Simulation provides a safe method for teaching ... refine techniques and build confidence, without putting ... such as augmented reality, will now provide ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)... Colo. , Sept. 5, 2017 Sapheneia ... XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party Vendor ... existing CT scanners and allows compliance with current MITA ... Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically designed ... and alerts of potential radiation doses over a predefined ...
Breaking Medicine Technology:
Cached News: